Our Pricing

Mounjaro vs Wegovy: Clinical Comparison & Evidence-Based Guide

When comparing Mounjaro vs Wegovy, UK patients often ask which weight loss injection delivers superior results. Both are licensed GLP-1 receptor agonists manufactured by Novo Nordisk and Eli Lilly respectively, but they differ significantly in mechanism, efficacy, and cost. This evidence-based comparison examines clinical trial data, real-world outcomes, and practical considerations to help you make an informed choice with your prescriber.

Mounjaro vs Wegovy: Active Ingredients & Mechanism of Action

The fundamental difference in the Mounjaro vs Wegovy comparison lies in their active ingredients and pharmacological mechanisms. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist, whilst Wegovy contains semaglutide, a selective GLP-1 receptor agonist [1]. This dual-action mechanism gives Mounjaro a theoretical advantage in metabolic regulation, targeting both incretin pathways simultaneously rather than one.

Tirzepatide's dual agonism means it activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors, enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying through two complementary pathways [1]. Semaglutide works exclusively through GLP-1 receptors, achieving similar metabolic effects but through a single mechanism. Both medications reduce appetite centrally via hypothalamic pathways, but tirzepatide's additional GIP activity may contribute to enhanced fat metabolism and improved insulin sensitivity [2].

Mounjaro vs Wegovy Weight Loss Results: Clinical Trial Data

Head-to-head clinical data comparing Mounjaro vs Wegovy directly is limited, but individual trial programmes provide robust comparative context. The SURMOUNT-1 trial demonstrated that tirzepatide (Mounjaro) achieved average weight loss of 15-22.5% of body weight over 72 weeks, depending on dose [2]. By comparison, the STEP 1 trial showed semaglutide 2.4mg (Wegovy) delivered average weight loss of 14.9% over 68 weeks [3].

At maximum doses, Mounjaro 15mg produced superior weight reduction compared to Wegovy 2.4mg in indirect comparisons, with approximately 22.5% versus 14.9% total body weight loss respectively [2][3]. However, individual response varies significantly based on baseline BMI, adherence, lifestyle modifications, and metabolic factors. Both medications require concurrent dietary changes and increased physical activity to optimise outcomes, as confirmed by NICE guidance on weight management interventions [4].

Real-World Effectiveness Beyond Trials

Real-world evidence suggests both Mounjaro and Wegovy maintain clinically significant weight loss beyond controlled trial settings, though adherence rates and tolerability influence long-term outcomes. UK prescribers report that patients on tirzepatide may experience slightly greater weight reduction in the first six months, but semaglutide often demonstrates better gastrointestinal tolerability in clinical practice. Subject to individual assessment, your prescriber will consider your medical history, previous medication responses, and weight loss goals when recommending between these options.

Mounjaro vs Wegovy Dosing & Treatment Schedules

Dosing protocols differ substantially in the Mounjaro vs Wegovy comparison, affecting both convenience and tolerability. Mounjaro follows a monthly escalation schedule starting at 2.5mg weekly, increasing to 5mg, 7.5mg, 10mg, 12.5mg, and maximum 15mg over approximately five months [1]. Wegovy uses a faster escalation: 0.25mg weekly for four weeks, then 0.5mg, 1mg, 1.7mg, reaching maintenance dose of 2.4mg within 16-20 weeks [3].

Both medications are administered as once-weekly subcutaneous injections using pre-filled pens. The slower titration schedule of Mounjaro may reduce gastrointestinal side effects during dose escalation, whilst Wegovy's faster ramp-up allows patients to reach therapeutic doses sooner. UK prescribers typically assess tolerability at each dose increase and may pause escalation if side effects occur, ensuring treatment remains tolerable whilst maximising efficacy.

Mounjaro vs Wegovy Side Effects & Safety Profile

The side effect profiles of Mounjaro vs Wegovy are broadly similar, reflecting their shared GLP-1 mechanism. The most common adverse effects for both medications include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, typically most pronounced during dose escalation [2][3]. In clinical trials, approximately 44% of Mounjaro patients and 44% of Wegovy patients experienced nausea, though severity varied.

Serious but rare side effects include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies but not confirmed in humans). Both medications carry a boxed warning regarding thyroid medullary carcinoma risk and are contraindicated in patients with personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 [1][3]. UK prescribers conduct thorough medical history reviews during consultation to identify contraindications before prescribing either medication.

Managing Side Effects in Clinical Practice

UK clinical experience suggests gastrointestinal side effects can be minimised through slower dose escalation, smaller meal portions, and avoiding high-fat foods. Patients should report persistent vomiting, severe abdominal pain, or signs of pancreatitis immediately to their prescriber. Both Mounjaro and Wegovy require ongoing clinical monitoring, with regular review of tolerability, weight loss progress, and metabolic parameters throughout treatment.

Mounjaro vs Wegovy Cost & UK Availability

Cost represents a significant consideration in the Mounjaro vs Wegovy comparison for UK patients. At Cured Pharmacy, Mounjaro is available from £124.99 per month following online clinical assessment, whilst Wegovy starts from £124.99 monthly, making it the more affordable option for many patients [5]. Both medications require private prescription in the UK, as NHS availability remains limited to specialist weight management services meeting strict eligibility criteria.

Supply stability has historically favoured Mounjaro, which has maintained consistent UK availability since launch. Wegovy experienced significant supply disruptions throughout 2022-2023 due to global demand, though availability has improved substantially in 2024. When comparing Mounjaro vs Wegovy, patients should consider both upfront cost and long-term treatment sustainability, as weight loss medications typically require 12-24 months of continuous use to achieve and maintain optimal results [4].

Mounjaro vs Wegovy: Which Should You Choose?

Choosing between Mounjaro vs Wegovy depends on individual clinical factors, budget, and treatment goals. Mounjaro may be preferable for patients seeking maximum weight loss potential and who can accommodate the higher cost, whilst Wegovy offers proven efficacy at a more accessible price point. Both medications require commitment to lifestyle modification, regular clinical monitoring, and long-term adherence to maintain weight loss.

Your UK prescriber will assess your BMI, medical history, previous weight loss attempts, contraindications, and personal preferences during consultation. At Cured Pharmacy, our clinical team provides personalised recommendations based on your individual circumstances, ensuring you receive the most appropriate treatment under ongoing pharmacist supervision. All prescriptions are subject to clinical approval by our UK-registered prescribers, with Superintendent Pharmacist Tarun Kumar (GPhC 2233073) overseeing dispensing and patient safety protocols.

Starting Your Weight Loss Journey

Whether you choose Mounjaro or Wegovy, success requires combining medication with sustainable dietary changes and increased physical activity. UK clinical guidelines recommend structured weight management programmes alongside pharmacotherapy, targeting 5-10% weight loss initially with potential for greater reduction over extended treatment [4]. Our clinical team provides ongoing support throughout your treatment journey, with regular check-ins to monitor progress, manage side effects, and adjust treatment as needed.

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management. NICE Clinical Guideline [CG189]. [accessed 15 August 2026]
5. Cured Pharmacy. (2024). Weight loss treatment pricing and availability. Retrieved from https://curedpharmacy.com/collections/weight-loss [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.